Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasudil eye drops in retinopathy of prematurity
NCT04191954Phase 3Unknown
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jun 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in retinopathy of prematurity (ROP) comparing Fasudil Group with Placebo Group (2 arms). Primary endpoint: Stimulation of normal retinal vascularization and disease progression inhibition at 3 months. Status: unknown.
02
Drugs
fasudil
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT04191954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04191954.